What is ABEC?
Since its inception in 1974, ABEC has been a pivotal force in delivering customized single-use, stainless steel, and hybrid solutions and services tailored for the biopharmaceutical manufacturing sector. A substantial portion of the world's pharmaceutical and biotech firms rely on ABEC's expertise, with many of today's leading therapies being manufactured using processes and equipment that ABEC has engineered, built, installed, and serviced. The company's distinct value proposition is built upon decades of experience, comprehensive in-house capabilities, a flexible and customized approach, and a proven track record of credibility. Whether clients are looking to expand capacity or enhance existing operations, ABEC's turn-key solutions and support services are designed to reduce overall costs and accelerate time-to-market while maximizing productivity.
How much funding has ABEC raised?
ABEC has raised a total of $4M across 2 funding rounds:
Debt
$2M
Debt
$2M
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
What's next for ABEC?
The substantial enterprise-level funding and recent strategic investment signal a period of significant growth and potential expansion for ABEC. This capital infusion is likely to be directed towards enhancing manufacturing capabilities, further developing innovative solutions for the biopharmaceutical industry, and potentially expanding its global reach. Given ABEC's history of providing critical equipment and services for therapy manufacturing, this backing will enable the company to meet the increasing demands of pharmaceutical and biotech clients, reinforcing its role as a key partner in bringing life-saving treatments to market.
See full ABEC company page
